Through case studies involving predictive modeling and automated image assessment, the sources demonstrate how data-driven workflows can identify critical production factors. Ultimately, this AI-driven approach seeks to accelerate decision-making and optimize biological processes to significantly enhance patient outcomes.

Stopping AI Hallucinations in CGT Manufacturing

AiCella, Inc., led by CEO Geoffrey Stephens, is leveraging artificial intelligence to transform the complex field of cell and gene therapy manufacturing. By utilizing their proprietary Insights platform, the company aims to resolve production bottlenecks and lower the high costs currently associated with these life-saving treatments. The technical framework incorporates a variety of machine learning algorithms and deep learning models to predict manufacturing outcomes and improve the quality of products like CAR-T and iPSC cells.